Results Healthcare   |   Results International

Insights

We add value by understanding our sectors inside out, and release regular industry research and reports

Results Healthcare has advised UCB on its divestment of Alprostadil products to Advanz Pharma

By Kevin Bottomley, Annabelle Guillermo 02 Apr 2020

Results Healthcare is pleased to announce it was the exclusive corporate finance advisor to UCB, a global biopharmaceutical company focused on neurology and immunology, on its divestment of the rights to a portfolio of Alprostadil products in 10 European Union countries, as well as the United Kingdom, Russia, Ukraine and Brazil, to Advanz Pharma.

This transaction is testament to Results Healthcare’s expertise in advising companies in the healthcare and life sciences sector, which follows Duke Street’s recent acquisition of Kent Pharmaceuticals.

The alprostadil product portfolio consists of two established, niche, injectable Prostaglandin E1 formulations for the treatment of erectile disfunction and peripheral arterial occlusive disease. Alprostadil is marketed under the brand names of Prostavasin®, Viridal®, Vasaprostan® and Edex®.

 

Read the press release here

 

Kevin Bottomley

Partner

Contact Kevin

Annabelle Guillermo

Director

Contact Annabelle

Insights

Weekly Public Healthcare Sector Analysis, News, Blogs & White Papers

View our insights     SUBSCRIBE

Connect with us

Follow Results Healthcare on Twitter Follow Results Healthcare on LinkedIn

Your Nearest Office